Gastrointestinal side effects are the most commonly reported adverse effects of tirzepatide, with clinical trials showing dose-dependent rates: nausea (20-33%), diarrhea (12-23%), vomiting (9-16%), constipation (11-17%), and abdominal pain
naltrexone + bupropion * A note about oral options: These forms are not FDA approved, and their bioavailability, stability, and clinical equivalence to approved products are not established
Mounjaro (tirzepatide) is a prescription drug developed by Eli Lilly
Most practitioners restart tirzepatide at a lower dose than the equivalent semaglutide dose to allow GIP receptor adaptation, then titrate upward based on response
This means it activates two hormone receptors simultaneously: the GLP-1 receptor (the same target semaglutide hits) and the GIP receptor (glucose-dependent insulinotropic polypeptide), which semaglutide does not touch at all
This triple action aims to enhance weight loss and metabolic benefits beyond what tirzepatide offers